Advanced searches left 3/3
Search only database of 8 mil and more summaries

Diagnosing Ovarian Cancer

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Only about 20% of ovarian cancers are found at an early stage. When Ovarian Cancer is found early, about 94% of patients live longer than 5 years after diagnosis. Ways To find Ovarian Cancer Early Regular Women's Health exams During pelvic exam, health care professional feels ovaries and uterus for size, shape, and consistency. The Pelvic exam can be useful because it can find some female cancers at an early stage, but most early Ovarian tumors are difficult or impossible to feel. Pelvic exams may, however, help find other cancers or female conditions. Women should discuss the need for these exams with their doctor. Screening tests used for cervical cancer, such AS Pap test or HPV test, are effective tests for Ovarian Cancer. Rarely, ovarian cancers are found through Pap tests, but usually they are at an advanced stage. See doctor if you have symptoms. Early cancers of ovaries often cause no symptoms. Symptoms of Ovarian Cancer can also be caused by other, less serious conditions. By time Ovarian Cancer is considered AS possible cause of these symptoms, it usually has already spread. Also, some types of Ovarian Cancer can rapidly spread to nearby organs. Prompt attention to symptoms may improve the odds of early diagnosis and successful treatment. If you have symptoms similar to those of Ovarian Cancer almost daily for more than a few weeks, report them right away to your health care professional. Screening tests For Ovarian Cancer Screening tests and exams are used to detect disease, like cancer, in people who do have any symptoms. There has been a lot of research to develop screening test for Ovarian Cancer, but there hasnt been much success so far. 2 tests used most often to screen for Ovarian Cancer are transvaginal Ultrasound and CA-125 blood test. Tvus is a test that uses sound waves to look at the uterus, Fallopian tubes, and ovaries by putting Ultrasound wand into the vagina. It can help find mass in the ovary, but it can't actually tell if mass is cancer or benign. When it is used for screening, most of mass found are not cancer. The CA-125 blood test measures the amount of protein called CA-125 in blood. Many women with Ovarian Cancer have high levels of CA-125. This test can be a useful AS tumor marker to help guide treatment in women known to have Ovarian Cancer, because high levels often go down if treatment is working. But checking CA-125 levels has not been found to be AS useful AS screening test for Ovarian Cancer. The problem with using this test for Ovarian Cancer Screening is that high levels of CA-125 are more often caused by common conditions such AS endometriosis and pelvic inflammatory disease. Also, not everyone who has Ovarian Cancer has a high CA-125 level.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Coping and support

Diagnosis of ovarian Cancer can leave you and your loved ones feeling uncertain, anxious and overwhelmed. There are important treatment decisions to make, emotional concerns to manage, and insurance and financial paperwork to organize, among other practical concerns. It is helpful to keep in mind that there are many sources of information and support for people coping with ovarian cancer. By learning about this diagnosis and its treatment options, Communicating With Your Health Care Team, and surrounding yourself with a support network, you will be better able to manage ovarian cancer and experience a better quality of life. View all of Cancer Care's resources to help you better cope with ovarian Cancer information presented in this publication is provided for your general information only. It is not intended as medical advice and should not be relied upon as a substitute for consultations with qualified health professionals who are aware of your specific situation. We encourage you to take information and questions back to your individual Health Care provider as a way of creating dialogue and partnership about Your Cancer and Your Treatment.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Tests to diagnose ovarian cancer

After our doctors carefully review your medical history and your familial risk of developing ovarian cancer, and complete the pelvic exam, they will conduct a combination of biopsies and imaging tests. Results from these tests are reviewed regularly by a dedicated gynecology team of surgeons, medical oncologists, and radiation oncologists at weekly tumor board meeting. This team will determine the best course of treatment specific to your type of ovarian cancer. There is no standard screening test to identify ovarian cancer. Diagnosis of ovarian cancer begins with a pelvic exam with your doctor, which can be helpful in identifying mass on either side of the uterus. Transvaginal ultrasound: procedure in which high-energy sound waves bounce off internal tissues or organs, such as the vagina, uterus, fallopian tubes, and bladder. Wave echoes form picture of body tissues called sonogram. Blood test: test to measure substance in blood called CA-125. This test is used to monitor progress of treatment. Ct Scan and Surgery: When the presence of ovarian cancer is detect, CT Scan or another radiologic procedure is performed to determine the extent of the disease. If the disease appears resectable, surgery is performed to make a definitive diagnosis and remove the tumor. If the disease does not appear to be resectable, biopsy is performed to make definitive diagnosis and determine course of treatment.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Inherited gene mutations

Background Breast Cancer is the most commonly diagnosed cancer in women. In 2005, there were about 3000 incident cases of Breast Cancer in Norway. Ovarian Cancer is less common, with about 400 cases each year. Although Breast Cancer is relatively common, only about 5-10% of cases are due to inheritance of highly penetrant Cancer susceptibility genes. Genes are also associated with an increased risk of Ovarian Cancer. Two main genes that confer susceptibility to Breast and Ovarian Cancer are the BRCA1 gene and the BRCA2 gene. Mutations in these genes are associated with both Hereditary Breast Cancer and Hereditary Ovarian Cancer. One characteristic of inherit Breast and Ovarian Cancer is that cancer usually appears at a younger age. There is a question if genetic testing can reduce incidence and morbidity of Cancer more than existing strategy based on documenting families with inherited predisposition to Cancer. The Directorate for Health and Social Affairs has asked the Norwegian Knowledge Centre for Health Services to summarize documentation of genetic testing of BRCA1 and BRCA2 and clinical outcome of testing. Methods We performed search for systematic reviews in the Cochrane Library and Health technology Assessment databases until September 2007. Results Data has been gathered from four systematic reviews that have summarise published literature on Genetic testing for BRCA1 and BRCA2 for Breast and Ovarian Cancer. Brca1 and BRCA2 are very large genes. Since the cloning of BRCA1 and BRCA2, more than a thousand mutations have been identified in these genes. From published literature, there is no compelling evidence to suggest that one genetic test performs better than another. To ensure a full mutation screen, more than one method needs to be used. Different populations have different mutations. Hence, type of mutation analysis required often depends on the population or subpopulations. Individuals from families with known mutations can more easily be tested specifically for them. Populations where specific BRCA mutations are clustered because of common ancestor are called founder populations. Cancer risk in family history risk groups is estimated by determining the prevalence of mutation and its penetrance for Breast and Ovarian Cancer. The prevalence of mutations varies according to the geographic and ethnic origin of the population. Few direct measures of the prevalence of clinically important BRCA1 or BRCA2 mutations in the general population have been publish. Models have estimated prevalence to be about 1 in 397 in the general population. Systematic reviews find that many women with Breast Cancer who are mutation carriers report no family history of Breast or Ovarian Cancer. A small number of clinically significant BRCA1 and BRCA2 mutations have been found repeatedly in different families, such as four founder mutations most common in the Norwegian population. The prevalence of each mutation differs according to different parts of the country.


Risks

Lifetime Risk of breast cancer 50% to 85% Risk of breast cancer before age 50 30% to 50% Lifetime Risk of ovarian cancer BRCA1 gene mutation 25% to 50% BRCA2 gene mutation 15% to 30% Developing second breast cancer 40% to 60% Lifetime Risk of breast cancer BRCA1 gene mutation 1% to 2% BRCA2 gene mutation 6% Risk of prostate cancer BRCA1 gene mutation some increase Risk BRCA2 gene mutation 20% Men with BRCA2 gene mutation have significantly increase Risk of Developing more aggressive prostate cancer before age 65 and therefore screening should begin at age 40.


What causes HBOC?

Most BReast and ovarian cancers are sporadic, meaning they occur by chance with no known cause. Most women who have BReast or ovarian CAncer do not have HBOC. Currently, it is estimated that less than 1% of the general population has mutation in BRCA1 or BRCA2 genes, and up to 10% of women and 20% of men diagnosed with BReast CAncer have mutation in 1 of these genes. About 10% to 30% of women younger than 60 are diagnosed with triple-negative BReast CAncer, which are cancers that do not have receptors for estrogen, progesterone, and HER2, have BRCA1 or BRCA2 gene mutation, and others will have mutations in other BReast CAncer risk genes. Therefore, doctors recommend that women with triple-negative BReast CAncer receive genetic counseling and genetic testing. Hboc is most common in families who have had multiple cases of BReast CAncer and / or ovarian CAncer on same side of the family. In families with 4 or more cases of BReast CAncer diagnosed before age 60, chance of HBOC is about 80%. To compare, chance of finding HBOC when only 1 woman has had BReast CAncer diagnosed before age 50 is estimated to be 10% or less. Families with Ashkenazi Jewish ancestry have increased chance of having HBOC. There are 3 specific gene mutations, know as founder mutations, that are common in these families: 185delAG in BRCA1 5382insC in BRCA1 6174delT in BRCA2. It is estimated that about 1 person out of 40 people with Ashkenazi Jewish ancestry has 1 of these 3 mutations. Approximately 1 in 10 women with BReast CAncer and 1 in 3 women with ovarian CAncer in Ashkenazi Jewish families have 1 of BRCA1 or BRCA2 gene mutations. If a person has BRCA2 mutation, it is important for other prospective parents to also be tested before pregnancy. This is particularly true for those of Ashkenazi Jewish ancestry among whom the risk of having genetic mutation is higher. If both parents carry BRCA2 gene mutation, there is a 25% risk of having a child with Fanconi anemia, which is an inherited disorder, associated with physical abnormalities, increased risk of blood cancers, and other serious problems. Fanconi anemia is inherited in an autosomal recessive pattern, meaning that if a child inherits copy of BRCA2 gene with mutation from each parent, he or she will be born with the disease.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Stages of ovarian cancer

Table

StageRelative 5-Year Survival Rate
I90%
IA94%
IB92%
IC85%

Staging is a process of finding out how much cancer there is in a person's body and where it is locate. Its how doctors determine the stage of person's cancer. For most types of cancer, doctors use staging information to help plan treatment and to predict persons outlook. Although each person's situation is different, cancers with the same stage tend to have similar outlooks and are often treated the same way. Cancer Stage is also a way for doctors to describe the extent of cancer when they talk with each other about persons cancer. While medical standard is to refer to stages using Roman numerals, stages are also sometimes written as Stage 1, Stage 2, Stage 3 and Stage 4. Each of these stages, except Stage IV, is divided into, B, and C.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

Table2

StageRelative 5-Year Survival Rate
II70%
IIA78%
IIB73%
IIC57%

Table3

StageRelative 5-Year Survival Rate
III39%
IIIA59%
IIIB52%
IIIC39%

Table4

StageSurvival Rate
190%
1A94%
1B92%
1C85%
270%
2A78%
2B73%
339%
3A59%
3B52%
3C39%
417%
* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Lab tests

Ovarian Cancer is uncontrolled growth of cells within a woman's ovary. Ovaries are reproductive glands that are located on either side of the uterus in the lower abdomen. To produce hormones Estrogen and progesterone that are responsible for development of secondary sexual features and regulation of the reproductive cycle. To develop and release egg into the fallopian tube once month during childbearing years, ovarian cancer is the fifth most common cause of cancer death in women. According to the American Cancer Society, life-time risk of developing ovarian cancer is about 1 in 78. Acs estimates that about 22 500 new cases are diagnosed each year in the United States and nearly 14 000 women die of it. Invasive ovarian Cancer is more common cause of death than more prevalent and easily detected cervical Cancer and uterine Cancer. Ovarian Cancer is more difficult to detect, so it is often diagnosed at later stages, when it is more difficult to treat. Ovarian tumors can be non-cancerous or cancerous. It is not usually possible to tell whether a tumor is cancerous until the ovary has been biopsied or removed or cancer has spread to other parts of the body. Ovarian tumors fall into three categories: epithelial tumors-begin in epithelial cells covering outside of the ovaries. Germ cell tumors-occur in egg-producing cells and are more often seen in younger women. Stromal tumors-derive from connective tissues of the ovary that produce Estrogen and progesterone while benign tumors do not spread, cancerous ovarian tumors will spread if left undiagnosed and untreated-first throughout the ovary, then to the uterus, bladder, rectum, and lining of the abdomen. Eventually, cancerous cells will reach lymph nodes and spread throughout the body. The main risk factor for ovarian cancer is family history of ovarian cancer on either your mother's or father's side of the family. According to the American Cancer Society, about 5% to 10% of ovarian cancers develop from inherited risk. Some examples include: hereditary breast and ovarian Cancer syndromeinherited harmful genetic variants in BRCA1 and BRCA2 genes are associated with significantly increased lifetime risk of developing ovarian Cancer. For women with BRCA1 pathogenic variants, risk is estimated to be 35-70% and for women with BRCA2 pathogenic variants it is 10-30%. Women without these pathogenic variants have a lifetime risk of about 2%. Hereditary nonpolyposis colon Cancer inherits pathogenic variants in several genes are associated mainly with increased risk of colon Cancer, but women may also have a higher risk of ovarian Cancer. Almost half of ovarian cancers are found in women 63 years of age or older. Most ovarian cancers develop after menopause. Raceovarian cancers are more common in Caucasian women than in African American women.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Emma's story

When a child complains of a stomachache and has fever, it is easy to assume the bug is to blame. In Emma Allred's case, it was Ovarian Cancer. At age 10, Emma begins feeling sick during a trip to Disney World. When the family returned home, her mother Nina checked her stomach to see where it was tender and felt mass. Not knowing what was normal, I took her to ER, Nina told People. They do CT scan and said that she had a mass in her abdomen the size of a tissue box. The fever was probably because the mass was so huge it was pressing on her lungs. Doctors diagnosed Emma with Ovarian Cancer and said she had to have her right ovary remove. Emma then went through three rounds of chemotherapy over the next three months. She was Cancer-free from December 2013 until July 2015, when her doctor found another large tumor in her lower abdomen during a routine check-UP. It was remove, and she and her family decided to undergo surveillance instead of chemotherapy. She is currently in remission, but her doctor discovered another mass on the surface of her liver, which will be removed on November 1. Now 13, Emma was approached by her local Make-AWish foundation and, after thinking about it for few weeks, she decided she wanted to help the homeless. The foundation helped Emma hold a food drive to benefit local shelters, collecting more than 13 000 pounds of food. Emmas story is amazing and also terrifying, but Cassandra M. Kelleher, MD, pediatric surgeon and surgical director of Neonatal Intensive Care Unit at MassGeneral Hospital for Children, told SELF that Ovarian Cancer isnt unheard of in children. I see it fairly often, but it is extremely rare in the greater population, she say. Approximately 1 percent of Ovarian Cancer cases reported each year are in girls under 18, Don S. Dizon, MD, FACP, clinical co-director of gynecologic at Massachusetts General Hospital Cancer Center, told SELF. According to the Ovarian Cancer National Alliance, estimate 22 280 new cases of Ovarian Cancer will be diagnosed this year, and 14 240 women will die of the disease. The organization also notes that ovarian cancer rates are highest in women aged 55 to 64, but half of women are younger than 63 when diagnose. But ovarian cancer in children is often different from ovarian cancer adult women can develop, Dizon say. It is extremely rare for children to get epithelial Ovarian Cancer, most common form of Ovarian Cancer in adult women, he say. It affects tissue covering the ovary. Non-epithelial ovarian cancers are more common in children than in adults, and they include germ cell tumors, or tumors in egg cells of the ovary, he say. That's kind of Ovarian Cancer Emma had. Dizon says it is largely unknown why Ovarian Cancer happens in some children.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Blood test (CA125 test)

The Ca 125 test measures the amount of protein CA 125 in your blood. The CA 125 test may be used to monitor certain cancers during and after treatment. In some cases, CA 125 test may be used to look for early signs of ovarian cancer in people with very high risk of disease. The CA 125 test isn't accurate enough to use for ovarian cancer screening in general because many noncancerous conditions can increase CA 125 level. Many different conditions can cause an increase in CA 125, including normal conditions, such as menstruation, and noncancerous conditions, such as uterine fibroids. Certain cancers may also cause increased level of CA 125, including ovarian, endometrial, peritoneal and fallopian tube cancers.


Results

Results of the CA 125 test are measured in units per milliliter. The normal value is less than 46 U / mL. If your CA 125 level is higher than normal, you may have a benign condition, or the test result could mean that you have ovarian, endometrial, peritoneal or fallopian tube cancer. Your doctor may recommend other tests and procedures to determine your diagnosis. If you 've been diagnosed with ovarian, endometrial, peritoneal or fallopian tube cancer, decreasing CA 125 level often indicates that cancer is responding to treatment. Rising CA 125 level may indicate return or continued growth of cancer. The number of normal and noncancerous conditions can cause elevated CA 125 level, including: endometriosis Liver disease, Menstruation Pelvic inflammatory disease Pregnancy Uterine fibroids. None of the major professional organizations recommend using CA125 as a screening test for those with an average risk of ovarian cancer.


What is a CA-125 blood test?

This test measures the amount of protein called CA-125 in the blood. Ca-125 levels are high in many women with ovarian cancer. Ovaries are a pair of female reproductive glands that store ova and make female hormones. Ovarian Cancer happens when there is uncontrolled cell growth in a woman's ovary. Ovarian Cancer is the fifth most common cause of Cancer death in women in the US because high CA-125 levels can be sign of other conditions besides ovarian Cancer, This test is not used to screen women at low risk for disease. The CA-125 blood test is most often done on women already diagnosed with ovarian cancer. It can help find out if cancer treatment is working, or if your cancer has come back after you have finished treatment. Other names: Cancer Antigen 125, glycoprotein Antigen, ovarian Cancer Antigen, CA-125 tumor marker

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Ovarian cancer research and studies

Researchers are also exploring new ways to treat platinum-resistant ovarian cancer. When platinum resistance occur, standard first-line chemotherapy drugs like carboplatin and cisplatin are ineffective. The future of PARP inhibitors will be in identifying what other drugs can be used in combination with them to treat tumors that show unique characteristics. Recently, some promising therapies have started clinical trials, such as a potential vaccine against recurrent ovarian cancers that expresses survivin protein. In May 2020, clinical trial results were published for a potential new antibody-drug conjugate to treat platinum-resistant ovarian cancer. New targeted therapies are being study, including antibody navicixizumab, ATR inhibitor AZD6738, and Wee1 inhibitor adavosertib. All have shown signs of anti-tumor activity. Gene therapies target people's genes to treat or cure disease. In 2020, phase III trial for gene therapy VB-111 will continue with promising results. In 2018, FDA fast-track protein therapy called AVB-S6-500 for platinum-resistant ovarian cancer. This aims to prevent tumor growth and cancer spreading by blocking key molecular pathway. Ongoing clinical trial combining immunotherapy with existing approved therapies has shown promise. The 2019 study examines targeted treatments for those with more advanced stages of this cancer. Ovarian cancer treatment primarily focuses on surgery to remove ovaries and uterus and chemotherapy. As a result, some women will experience menopause symptoms. 2015 article look at intraperitoneal chemotherapy. This study found that those who received IP therapy had a median survival rate of 61. 8 months. This was an improvement as compared to 51. 4 months for those who receive standard chemotherapy.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.